Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection.

European urology·2024
Same author

Successful completion of large, low-cost randomized cancer trials at an academic cancer center.

Clinical trials (London, England)·2024
Same author

Testosterone Therapy in Men After Radical Prostatectomy for Low-Intermediate Organ-Confined Prostate Cancer.

The Journal of urology·2024
Same author

Re: Early Prostate Cancer Deaths Among Men with Higher vs Lower Genetic Risk.

European urology·2024
Same author

Transperineal vs Transrectal Prostate Biopsy-The PREVENT Randomized Clinical Trial.

JAMA oncology·2024
Same author

Clinical utility of an artificial intelligence radiomics-based tool for risk stratification of pulmonary nodules.

JNCI cancer spectrum·2024

Related Experiment Video

Updated: May 27, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Risk-based prostate cancer screening.

Xiaoye Zhu1, Peter C Albertsen, Gerald L Andriole

  • 1Department of Urology, Erasmus MC University Medical Center, Rotterdam, The Netherlands. y.zhu@erasmusmc.nl

European Urology
|December 3, 2011
PubMed
Summary

Prostate cancer (PCa) screening using prostate-specific antigen (PSA) testing can identify at-risk men. Individualized risk assessment, considering factors beyond PSA, is crucial for informed decisions about early detection and potential harms.

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

Related Experiment Videos

Last Updated: May 27, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

Area of Science:

  • Urology
  • Oncology
  • Preventive Medicine

Background:

  • Mass prostate cancer (PCa) screening lacks established benefit-harm balance.
  • Current screening leads to harms like unnecessary biopsies and overtreatment.
  • Patient stratification is needed to identify men who benefit from early detection.

Purpose of the Study:

  • To critically review evidence on risk-based PCa screening.
  • To evaluate the role of prostate-specific antigen (PSA) in risk stratification.
  • To identify factors influencing PCa risk assessment.

Main Methods:

  • Literature search of the Medline database.
  • Manual review of reference lists and existing review articles.
  • Synthesis of current evidence on PCa risk factors and screening.

Main Results:

  • Prostate-specific antigen (PSA) is the primary predictor of PCa risk.
  • PSA levels can guide personalized screening frequency for up to 30 years.
  • Age, comorbidity, family history, and ethnicity modify PCa risk.
  • Risk calculators incorporating PSA show promise for identifying biopsy candidates.

Conclusions:

  • PSA testing forms the basis for risk-based prostate cancer assessment.
  • Shared decision-making between patient and physician is essential for PSA testing.
  • Balancing advantages and disadvantages is key for informed screening decisions.